Biotricity Reports Revenue Growth Amid Ongoing Financial Challenges in Q3 2024 Results

Biotricity Inc. (OTCBB: BTCY) has filed its quarterly report for the period ending December 31, 2024, revealing both advancements and challenges within the company.

Key Financial Metrics:

• Revenue: $3,619,108 for Q3 2024, up 21.7% from $2,972,972 in Q3 2023.
• Gross Profit: $2,763,968, representing a gross margin of 76.4%; improved from 72.9% year-over-year.
• Loss From Operations: Loss narrowed to $(168,982) from $(1,281,774) in Q3 2023.
• Net Loss: $(1,229,154) compared to $(2,808,091) for the same quarter last year, indicating progress in trend reduction.
• Accumulated Deficit: $137,419,652 as of December 31, 2024.
• Shares Outstanding: 24,751,756 shares as of February 18, 2025.

Positive Aspects:

• Revenue growth of 21.7% in Q3 2024 shows increased market penetration and effectiveness of sales efforts.
• Improved gross profit margin indicates better cost management and efficiency in operations.
• Decreased total operating expenses by 16.8% from the previous year, particularly in general and administrative costs.
• Continuing advancements in technology and product offerings, like the Bioflux and Biocore.

Negative Aspects:

• Persistent net losses indicate ongoing financial challenges, primarily driven by high interest and operational expenses.
• The company faces a working capital deficit of $16,280,084, raising concerns about liquidity.
• Heavy reliance on external financing, demonstrated by significant accrued interest on loans and promissory notes.
• Transitioning from Nasdaq to OTCBB raises challenges for visibility and trading volume.

The report highlights Biotricity's strategic focus on expanding its sales force and product development. While progress is being made in terms of revenue and margin improvements, the need for additional financing remains a concern that management is addressing with ongoing efforts to improve operational efficiency and pursue growth opportunities.

In summary, Biotricity Inc. has made strides in its operations and financial performance, reflecting growth potential. However, significant financial hurdles persist, and the company must navigate its liquidity issues while continuing to innovate in the competitive healthcare technology space.